Prosus unveils AI House Amsterdam to boost Europe’s artificial intelligence leadership

Fabricio Bloisi Group Chief Executive Officer and Executive Director Prosus N.V.
Fabricio Bloisi Group Chief Executive Officer and Executive Director - Prosus N.V.
0Comments

Prosus has announced the establishment of AI House Amsterdam, an initiative aimed at positioning Europe as a leader in artificial intelligence. The project is based within Prosus’ headquarters in Zuidas, Amsterdam, and will function as an innovation hub for startups, researchers, and policy leaders.

Fabricio Bloisi, CEO of Prosus, stated: “With AI House Amsterdam, we are doing what Europe urgently needs, concentrating ambition, talent and capital here to shape the future of AI everywhere.” He emphasized the potential for Europe to become home to its first trillion-dollar company.

Maarten Cleeren from Techleap expressed support for the initiative: “We welcome Prosus’s leadership with AI House Amsterdam. It is a valuable addition to the Dutch AI ecosystem.” Jelle Prins of Cradle also highlighted the importance of bringing together talented individuals through such hubs.

The launch aligns with Prosus’s ongoing commitment to fostering innovation across its global network. The company already invests significantly in AI and plans to expand its influence further with initiatives like AI House Amsterdam.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.